首页> 外文期刊>Current opinion in drug discovery & development >Achieving polymorph selectivity in the crystallization of pharmaceutical solids: basic considerations and recent advances.
【24h】

Achieving polymorph selectivity in the crystallization of pharmaceutical solids: basic considerations and recent advances.

机译:在药物固体结晶中实现多晶型物选择性:基本考虑因素和最新进展。

获取原文
获取原文并翻译 | 示例
           

摘要

Controlling the appearance of crystal polymorphs of pharmaceuticals is essential in developing robust large-scale crystallization processes in the pharmaceutical industry. This review describes many of the thermodynamic and kinetic factors that are important for controlling crystal polymorphism and discusses recent advances in the understanding of the molecular mechanisms of polymorph appearance. Case studies in the development of crystallization processes of pharmaceutical solids, where process analytical technology was applied to resolve the complexities introduced by crystal polymorphism, are discussed.
机译:控制药物晶体多晶型物的出现对于开发制药工业中强大的大规模结晶过程至关重要。这篇综述描述了对控制晶体多态性很重要的许多热力学和动力学因素,并讨论了对多晶型物出现的分子机理的理解的最新进展。讨论了药物固体结晶过程开发中的案例研究,其中应用了过程分析技术来解决由晶体多态性引起的复杂性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号